Adalimumab is a TNF-α inhibitor used in clinical practice in the treatment of many diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), and juvenile idiopathic arthritis [21]. Here, TNF is linked to juvenile idiopathic arthritis.